
-
Viridian Therapeutics NASDAQ:VRDN Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody in development for thyroid eye disease (TED). Viridian is headquartered in Boulder, Colorado , with research and development operations in Waltham, Massachusetts.
Location: 6200 Lookout Rd, Colorado, 80301-3319, US | Website: www.viridiantherapeutics.com | Industry: Medical Laboratories | Sector: Health Care and Social Assistance
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
747.7M
Cash
753.2M
Avg Qtr Burn
-49.25M
Short % of Float
14.58%
Insider Ownership
0.40%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VRDN-001 Details Thyroid Eye Disease | BLA Submission | |
VRDN-003 Details Thyroid Eye Disease | Phase 3 Data readout | |
VRDN-001 Details Thyroid Eye Disease | Phase 3 Update | |
VRDN-006 Details no known indication | Phase 1 Initiation | |
VRDN-008 Details no known indication | IND Submission |